Ilyang Pharm Capital Reinvestment Ratio
Ilyang Pharm capital reinvestment ratio. Ilyang Pharm (007570) has a Capital Reinvestment Ratio of 1.47x as of June 2025, meaning it reinvests 1% of its operating cash flow (₩2.26 Billion) in capital expenditures (₩3.32 Billion). See Ilyang Pharm (007570) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Ilyang Pharm (2003–2024)
Capital reinvestment ratio of Ilyang Pharm from 2003 to 2024. This chart tracks Ilyang Pharm's Capital Reinvestment Ratio across 12 annual periods. See 007570 FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
Ilyang Pharm Capital Reinvestment Ratio by Year (2003–2024)
Ilyang Pharm capital reinvestment ratio by year from 2003 to 2024. For the full cash flow conversion analysis, see Ilyang Pharm (007570) cash flow conversion.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 7.23x | ₩5.61 Billion | ₩40.62 Billion | ▲ +1391.3% |
| 2023 | 0.49x | ₩13.34 Billion | ₩6.47 Billion | ▲ +255.8% |
| 2022 | 0.14x | ₩29.94 Billion | ₩4.08 Billion | ▼ -29.2% |
| 2021 | 0.19x | ₩67.02 Billion | ₩12.91 Billion | ▲ +8.8% |
| 2020 | 0.18x | ₩57.48 Billion | ₩10.17 Billion | ▲ +194.7% |
| 2019 | 0.06x | ₩36.19 Billion | ₩2.17 Billion | ▼ -14.1% |
| 2018 | 0.07x | ₩22.12 Billion | ₩1.55 Billion | ▼ -44.5% |
| 2017 | 0.13x | ₩30.03 Billion | ₩3.78 Billion | ▼ -67.0% |
| 2016 | 0.38x | ₩26.98 Billion | ₩10.31 Billion | ▼ -4.3% |
| 2015 | 0.40x | ₩40.27 Billion | ₩16.07 Billion | ▼ -46.5% |
| 2014 | 0.75x | ₩18.63 Billion | ₩13.89 Billion | ▲ +1710.6% |
| 2003 | 0.04x | ₩10.08 Billion | ₩415.11 Million | — |